Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AXSM

AXSM - Axsome Therapeutics Inc Stock Price, Fair Value and News

82.30USD+3.36 (+4.26%)Market Closed
Watchlist

Market Summary

USD82.30+3.36
Market Closed
4.26%

AXSM Alerts

  • Big jump in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

AXSM Stock Price

View Fullscreen

AXSM RSI Chart

AXSM Valuation

Market Cap

3.9B

Price/Earnings (Trailing)

-16.3

Price/Sales (Trailing)

14.41

EV/EBITDA

-16.69

Price/Free Cashflow

-26.77

AXSM Price/Sales (Trailing)

AXSM Profitability

EBT Margin

-88.06%

Return on Equity

-125.27%

Return on Assets

-40.67%

Free Cashflow Yield

-3.74%

AXSM Fundamentals

AXSM Revenue

Revenue (TTM)

270.6M

Rev. Growth (Yr)

193.5%

Rev. Growth (Qtr)

23.77%

AXSM Earnings

Earnings (TTM)

-239.2M

Earnings Growth (Yr)

-61.09%

Earnings Growth (Qtr)

-58.61%

Breaking Down AXSM Revenue

Last 7 days

-4.2%

Last 30 days

8.9%

Last 90 days

55.0%

Trailing 12 Months

47.8%

How does AXSM drawdown profile look like?

AXSM Financial Health

Current Ratio

3.63

Debt/Equity

0.93

Debt/Cashflow

-0.82

AXSM Investor Care

Shares Dilution (1Y)

8.91%

Diluted EPS (TTM)

-5.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023144.6M182.5M223.4M270.6M
202200050.0M
20210000
20200000
2019197.9K178.4K158.9K139.4K
2018209.7K212.3K214.8K217.4K
2017407.5K340.7K273.9K207.1K
2016000474.3K
20150000
20140002.2M

Tracking the Latest Insider Buys and Sells of Axsome Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 15, 2023
coleman mark
acquired
40,428
3.67
11,016
-
Sep 15, 2023
coleman mark
sold
-828,241
75.1853
-11,016
-
Sep 15, 2023
coleman mark
sold
-1,396,190
75.1771
-18,572
-
Jan 03, 2023
coleman mark
acquired
22,751
1.3
17,501
-
Mar 15, 2022
coleman mark
acquired
4,544
1.3
3,496
-
Nov 19, 2021
jeffs roger
bought
147,350
37.3038
3,950
-
Nov 18, 2021
pizzie nick
bought
18,708
35.5
527
chief financial officer
Nov 18, 2021
pizzie nick
bought
14,967
34.9709
428
chief financial officer
Nov 18, 2021
coleman mark
bought
50,180
35.0914
1,430
-
Nov 17, 2021
saad mark e
bought
10,324
34.415
300
-

1–10 of 25

Which funds bought or sold AXSM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 22, 2024
SIERRA SUMMIT ADVISORS LLC
new
-
734,139
734,139
0.21%
Feb 20, 2024
Quarry LP
sold off
-100
-121,958
-
-%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
unchanged
-
3,363,110
27,594,800
0.45%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
sold off
-100
-4,543
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
548
10,084,000
11,665,000
-%
Feb 15, 2024
BARCLAYS PLC
added
1,041
14,095,000
15,270,000
0.01%
Feb 15, 2024
Financial Gravity Asset Management, Inc.
sold off
-
-48.00
48.00
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
875
875
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-26.08
-1,388,440
7,388,420
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-2.6
258,552
2,627,820
-%

1–10 of 37

Are Funds Buying or Selling AXSM?

Are funds buying AXSM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXSM
No. of Funds

Unveiling Axsome Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
fairmount funds management llc
4.9%
2,360,077
SC 13G/A
Feb 14, 2024
rtw investments, lp
9.5%
4,489,596
SC 13G/A
Feb 13, 2024
vanguard group inc
7.81%
3,696,766
SC 13G/A
Jan 26, 2024
blackrock inc.
6.8%
3,239,746
SC 13G/A
Jul 07, 2023
fairmount funds management llc
5.0%
2,344,980
SC 13G
Feb 14, 2023
venrock healthcare capital partners ii, l.p.
0.0%
0
SC 13G/A
Feb 14, 2023
fairmount funds management llc
4.6%
2,011,647
SC 13G/A
Feb 14, 2023
rtw investments, lp
6.9%
2,980,482
SC 13G
Feb 14, 2023
pfm health sciences, lp
3.2%
6
SC 13G/A
Feb 09, 2023
vanguard group inc
7.87%
3,417,628
SC 13G/A

Recent SEC filings of Axsome Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 23, 2024
10-K
Annual Report
Feb 20, 2024
8-K
Current Report
Feb 20, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report
Jan 04, 2024
8-K
Current Report
Dec 07, 2023
8-K
Current Report

Peers (Alternatives to Axsome Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
20.0B
1.8B
-23.99% -31.71%
-45.39
10.93
76.23% 61.08%
17.2B
2.4B
-4.89% -18.90%
102.64
7.11
15.42% 18.43%
13.6B
3.7B
-7.62% -26.87%
22.74
3.68
8.87% 75.42%
MID-CAP
8.5B
272.9M
-2.06% 34.31%
-14.04
31.17
141.38% 4.43%
6.0B
-
-3.85% 226.12%
-9.55
60.35
54.84% -25.61%
4.3B
631.9M
-12.60% 32.37%
-28.58
6.73
23.54% 31.53%
3.9B
270.6M
8.92% 47.81%
-16.3
14.41
440.80% -27.84%
3.8B
240.7M
-19.08% -10.99%
-12.71
15.68
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
24.39
4.34
81.69% -7.29%
653.3M
1.0B
-9.17% -57.89%
-1.19
0.62
-43.15% 58.48%
185.2M
4.9M
-14.18% -58.18%
-1.13
37.88
-57.57% 50.48%
124.0M
881.7K
289.54% 381.25%
-2.61
112.79
-77.61% -13.74%
4.1M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Axsome Therapeutics Inc News

Latest updates
AmericanBankingNEWS21 hours ago
Yahoo Finance21 Feb 202403:39 pm
Investor's Business Daily20 Feb 202409:04 pm

Axsome Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue23.8%71,530,00057,794,00046,700,00094,576,00024,371,10616,846,0008,820,000----------139,44892,96546,483-
Costs and Expenses41.6%169,804,000119,914,000111,757,000100,950,00084,288,66159,258,00048,001,00038,289,00032,608,04033,407,14230,847,687----------
Operating Expenses--------38,288,87232,608,04033,407,14230,847,68727,844,06127,744,23621,126,80117,778,83432,491,45724,428,17018,947,23513,448,21910,421,4739,450,315
  S&GA Expenses4.4%86,809,00083,188,00078,935,00074,191,00061,497,66140,892,00031,160,00025,704,00018,826,58820,226,88416,344,36111,248,37210,359,5076,331,3087,235,8774,970,0575,222,8993,111,6622,445,0772,818,3922,299,083
  R&D Expenses7.1%30,803,00028,767,00020,581,00017,793,00014,693,44714,877,00015,792,00012,585,00013,781,45313,180,25814,503,32616,595,68917,384,72914,795,49310,542,95727,521,40019,205,27115,835,57311,003,1427,603,0817,151,232
EBITDA Margin1.7%-0.82-0.83-0.93-1.01-3.58-888-898-901-901------------
Interest Expenses2.9%4,868,0004,730,0003,916,0003,216,0002,569,2922,531,0001,467,0001,119,0001,143,1251,169,1661,169,1671,143,750917,955416,836383,334379,167308,339383,334379,166216,667186,941
Income Taxes56.5%-295,000-678,000-617,0002,600,000-----------------
Earnings Before Taxes-57.4%-98,976,000-62,877,000-67,787,000-8,638,000-61,241,000-44,823,000-41,438,000-39,632,000-------------
EBT Margin1.9%-0.88-0.90-1.00-1.08-3.74-935-935-935-935------------
Net Income-58.6%-98,651,000-62,199,000-67,170,000-11,218,000-61,240,151-44,823,000-41,439,000-39,632,000-33,976,136-34,882,677-32,284,209-29,259,970-29,164,647-22,924,815-18,326,992-32,484,146-24,806,984-19,135,612-13,762,214-10,640,376-9,597,015
Net Income Margin2.1%-0.88-0.90-1.01-1.10-3.74-1,146-1,075-1,009-935-900-814-714---------
Free Cashflow43.7%-30,369,000-53,919,000-55,482,000-5,892,000-27,743,907-22,824,000-33,778,000-32,867,000-28,840,519-27,034,880-25,412,430-27,245,484---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-2.1%58860161238933133918189.0088.0011714316718620419119822144.0055.0044.0015.00
  Current Assets-1.5%50451252030424625210487.0087.0011514216518420319119822044.0055.0044.0015.00
    Cash Equivalents-7.3%38641743724720122873.0085.0086.0011514116518420219119722044.0054.0043.0014.00
  Inventory51.6%15.0010.009.008.004.002.0010.00--------------
  Net PPE-12.9%1.001.001.001.001.001.001.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00
  Goodwill0%12.0012.0012.0010.0010.0012.0012.0012.00-------------
Liabilities19.9%39733133327722218216574.0072.0074.0072.0071.0072.0068.0037.0042.0042.0038.0030.0027.0014.00
  Current Liabilities21.1%13911511510197.0060.0043.0025.0023.0025.0023.0022.0023.0020.0023.0026.0024.0019.0013.008.0011.00
  Long Term Debt-100.0%-17717714894.0094.0093.0049.0049.0049.0049.0049.0048.0048.0014.0016.0017.0019.0017.0019.004.00
    LT Debt, Current---------------7.005.003.001.002.001.003.00
    LT Debt, Non Current0.4%17817717714894.0094.0093.0049.0049.0049.0049.0049.0048.0048.0014.0016.0017.0019.0017.0019.004.00
Shareholder's Equity-29.1%19127027911211015715.0015.0016.0043.0071.0096.001141351541561797.0024.0017.001.00
  Retained Earnings-13.4%-835-736-674-607-596-535-490-448-409-375-340-308-278-249-226-208-175-151-132-118-107
  Additional Paid-In Capital2.0%1,0271,006954719706692505464425418412404393385381365355158156136108
Shares Outstanding0.1%47.0047.0047.0044.0043.0042.0039.0038.0038.0038.0038.0037.00---------
Float-------1,200---2,000---2,400---675--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations43.3%-30,362-53,548-55,349-5,821-27,562-22,758-33,537-32,653-28,840-26,776-25,393-27,215-20,553-15,734-18,895-23,273-17,567-10,626-8,681-9,499-9,793
  Share Based Compensation27.5%18,91514,84015,92212,94310,7689,19810,1627,5985,8895,7255,4563,7315,6062,8694,1482,1342,8141,1568891,256353
Cashflow From Investing98.1%-7.00-371-133-71.00-181-66.00-53,241-214--258-18.88-29.99-20.29-14.84-1.43-9.33-1.46-3.20---
Cashflow From Financing-100.0%-2.0033,370246,08051,5651,066176,95075,46431,1026904391,9718,0292,09027,42812,265630193,89351919,82238,1558,542

AXSM Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues [Abstract]   
Revenue$ 270,600$ 50,037 
Operating expenses:   
Cost of revenue (excluding amortization and depreciation)26,0655,198 
Research and development97,94457,947$ 58,061
Selling, general and administrative323,123159,25466,646
Loss in fair value of contingent consideration48,9183,298 
Intangible asset amortization6,3754,139 
Total operating expenses502,425229,836124,707
Loss from operations(231,825)(179,799)(124,707)
Interest expense, net(6,453)(7,335)(5,696)
Loss before income taxes(238,278)(187,134)(130,403)
Income tax expense(960)  
Net loss$ (239,238)$ (187,134)$ (130,403)
Net loss per common share, basic$ (5.27)$ (4.60)$ (3.47)
Net loss per common share, diluted$ (5.27)$ (4.60)$ (3.47)
Weighted average common shares outstanding, basic45,425,21240,655,94137,618,599
Weighted average common shares outstanding, diluted45,425,21240,655,94137,618,599
Product Sales   
Revenues [Abstract]   
Revenue$ 202,460$ 50,037 
License Revenue   
Revenues [Abstract]   
Revenue65,735  
Royalty Revenue   
Revenues [Abstract]   
Revenue$ 2,405  

AXSM Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 386,193$ 200,842
Accounts receivables, net94,82037,699
Inventories, net15,1354,320
Prepaid and other current assets8,1152,781
Total current assets504,263245,642
Equipment, net846722
Right-of-use asset - operating lease6,772420
Goodwill12,04210,310
Intangible asset, net53,28659,661
Non-current inventory and other assets11,02714,721
Total assets588,236331,476
Current liabilities:  
Accounts payable40,67938,605
Accrued expenses and other current liabilities90,50151,631
Operating lease liability, current portion1,267425
Contingent consideration, current6,4075,900
Total current liabilities138,85496,561
Contingent consideration, non-current73,30031,100
Loan payable, long-term178,07094,259
Operating lease liability, long-term7,035 
Total liabilities397,259221,920
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding)
Common stock, $0.0001 par value per share (150,000,000 shares authorized, 47,351,363 and 43,498,617 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively)54
Additional paid-in capital1,026,543705,885
Accumulated deficit(835,571)(596,333)
Total stockholders’ equity190,977109,556
Total liabilities and stockholders’ equity$ 588,236$ 331,476
AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
 CEO
 WEBSITEwww.axsome.com
 EMPLOYEES422

Axsome Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Axsome Therapeutics Inc? What does AXSM stand for in stocks?

AXSM is the stock ticker symbol of Axsome Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axsome Therapeutics Inc (AXSM)?

As of Mon Feb 26 2024, market cap of Axsome Therapeutics Inc is 3.9 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXSM stock?

You can check AXSM's fair value in chart for subscribers.

What is the fair value of AXSM stock?

You can check AXSM's fair value in chart for subscribers. The fair value of Axsome Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axsome Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXSM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axsome Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AXSM is over valued or under valued. Whether Axsome Therapeutics Inc is cheap or expensive depends on the assumptions which impact Axsome Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXSM.

What is Axsome Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Feb 26 2024, AXSM's PE ratio (Price to Earnings) is -16.3 and Price to Sales (PS) ratio is 14.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXSM PE ratio will change depending on the future growth rate expectations of investors.